FiercePharma23h
Sanofi's consumer health arm Opella secures FDA green light to pursue OTC Cialis study
After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...
Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch
Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...
Hosted on MSN3mon
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
With a portfolio of 100 leading brands ... counter and vitamins, minerals, and supplements market, serving over 500 million consumers worldwide. Opella’s journey to independence aligns with ...
Sanofi's Opella: FDA Lifts Clinical Hold On OTC Cialis Trial
Sanofi's Consumer Healthcare division, Opella, announced that the U.S. Food and Drug Administration has lifted a clinical hold on its ...
pharmaphorum5y
Sanofi licenses OTC Tamiflu rights for the US market
Sanofi isn’t saying how much it is paying for the OTC rights to Tamiflu in the US ... as Tamiflu continues to decline, with the older brand reduced to just $179m in the first quarter of this ...
MM&M5d
Skyrizi claims year-end TV ad crown among Rx, OTC pharma brands
Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.